262 related articles for article (PubMed ID: 14555519)
1. HLA-G is a potential tumor marker in malignant ascites.
Singer G; Rebmann V; Chen YC; Liu HT; Ali SZ; Reinsberg J; McMaster MT; Pfeiffer K; Chan DW; Wardelmann E; Grosse-Wilde H; Cheng CC; Kurman RJ; Shih IeM
Clin Cancer Res; 2003 Oct; 9(12):4460-4. PubMed ID: 14555519
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer.
Chen HX; Lin A; Shen CJ; Zhen R; Chen BG; Zhang X; Cao FL; Zhang JG; Yan WH
Hum Immunol; 2010 Sep; 71(9):892-8. PubMed ID: 20547193
[TBL] [Abstract][Full Text] [Related]
3. HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro.
He X; Dong DD; Yie SM; Yang H; Cao M; Ye SR; Li K; Liu J; Chen J
Ann Surg Oncol; 2010 May; 17(5):1459-69. PubMed ID: 20052552
[TBL] [Abstract][Full Text] [Related]
4. HLA-G and its relation to proliferation index in detection and monitoring breast cancer patients.
Sayed D; Badr G; Maximous D; Mikhail NN; Abu-Tarboush F; Alhazza IM
Tissue Antigens; 2010 Jan; 75(1):40-7. PubMed ID: 20196818
[TBL] [Abstract][Full Text] [Related]
5. Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer.
Jung YW; Kim YT; Kim SW; Kim S; Kim JH; Cho NH; Kim JW
Reprod Sci; 2009 Nov; 16(11):1103-11. PubMed ID: 19692629
[TBL] [Abstract][Full Text] [Related]
6. Characterization of HLA-G expression in renal cell carcinoma.
Li BL; Lin A; Zhang XJ; Zhang X; Zhang JG; Wang Q; Zhou WJ; Chen HX; Wang TJ; Yan WH
Tissue Antigens; 2009 Sep; 74(3):213-21. PubMed ID: 19531101
[TBL] [Abstract][Full Text] [Related]
7. Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer.
Cao M; Yie SM; Liu J; Ye SR; Xia D; Gao E
Tissue Antigens; 2011 Aug; 78(2):120-8. PubMed ID: 21726203
[TBL] [Abstract][Full Text] [Related]
8. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
[TBL] [Abstract][Full Text] [Related]
9. Quantification and identification of soluble HLA-G isoforms.
Rebmann V; LeMaoult J; Rouas-Freiss N; Carosella ED; Grosse-Wilde H
Tissue Antigens; 2007 Apr; 69 Suppl 1():143-9. PubMed ID: 17445190
[TBL] [Abstract][Full Text] [Related]
10. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer.
Simon I; Zhuo S; Corral L; Diamandis EP; Sarno MJ; Wolfert RL; Kim NW
Cancer Res; 2006 Feb; 66(3):1570-5. PubMed ID: 16452214
[TBL] [Abstract][Full Text] [Related]
11. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
[TBL] [Abstract][Full Text] [Related]
12. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release.
Morandi F; Levreri I; Bocca P; Galleni B; Raffaghello L; Ferrone S; Prigione I; Pistoia V
Cancer Res; 2007 Jul; 67(13):6433-41. PubMed ID: 17616704
[TBL] [Abstract][Full Text] [Related]
13. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.
Desmetz C; Bascoul-Mollevi C; Rochaix P; Lamy PJ; Kramar A; Rouanet P; Maudelonde T; Mangé A; Solassol J
Clin Cancer Res; 2009 Jul; 15(14):4733-41. PubMed ID: 19584157
[TBL] [Abstract][Full Text] [Related]
14. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage.
Vitale M; Pelusi G; Taroni B; Gobbi G; Micheloni C; Rezzani R; Donato F; Wang X; Ferrone S
Clin Cancer Res; 2005 Jan; 11(1):67-72. PubMed ID: 15671529
[TBL] [Abstract][Full Text] [Related]
15. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
17. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma.
Yie SM; Yang H; Ye SR; Li K; Dong DD; Lin XM
Am J Clin Pathol; 2007 Dec; 128(6):1002-9. PubMed ID: 18024326
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of human leukocyte antigen-G (HLA-G) messenger RNAs and proteins in normal human prostate and prostatic adenocarcinoma.
Langat DK; Sue Platt J; Tawfik O; Fazleabas AT; Hunt JS
J Reprod Immunol; 2006 Aug; 71(1):75-86. PubMed ID: 16616377
[TBL] [Abstract][Full Text] [Related]
19. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
20. Human kallikrein 14: a new potential biomarker for ovarian and breast cancer.
Borgoño CA; Grass L; Soosaipillai A; Yousef GM; Petraki CD; Howarth DH; Fracchioli S; Katsaros D; Diamandis EP
Cancer Res; 2003 Dec; 63(24):9032-41. PubMed ID: 14695222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
